Technical analysis of CDT Equity Inc. (CDT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clin...
Price Performance
| 1 month | -93.15% |
| 3 months | -98.06% |
| Year-to-date | -99.94% |
| 1 year | -99.99% |
52-Week Range
| 52-week High | $2360.00 |
| 52-week Low | $0.18 |
| Avg Volume (90d) | 1.4M |
Technical Indicators
| SMA 50 | $2.49 |
| SMA 200 | $126.40 |
| 30-day Volatility (annualised) | 231.7% |
| Price vs SMA 50 | -92.0% |
| Price vs SMA 200 | -99.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $710.00 | |
| 2025-11 | $507.50 | -28.5% |
| 2025-12 | $320.00 | -36.9% |
| 2026-01 | $272.50 | -14.8% |
| 2026-02 | $173.20 | -36.4% |
| 2026-03 | $51.00 | -70.6% |
| 2026-04 | $23.30 | -54.3% |
| 2026-05 | $10.40 | -55.4% |
| 2026-06 | $5.60 | -46.2% |
| 2026-07 | $2.93 | -47.7% |
| 2026-08 | $1.68 | -42.7% |
| 2026-09 | $0.20 | -88.2% |
Price
| Price | $0.20 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.01 |
| EV / EBITDA | 3.99 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.95 |
| Current Ratio | 2.14 |